The guideline on minimally invasive heart valve interventions will be evaluated by the Institute for Quality Assurance and Transparency in Health Care (IQTIG) in Germany

15

Mar 2018

On the 15th of February, 2018 the Federal Joint Committee (G-BA) has commissioned the Institute for Quality Assurance and Transparency in Health Care (IQTIG) to evaluate the guideline on minimally invasive heart valve interventions (MHI-RL), which came into force in July, 2015.

In this guideline the G-BA has set minimum quality standards for the implementation of minimally invasive heart valve interventions. If the hospital wishes to continue offering transcatheter aortic valve implantation (TAVI) or mitral clip valve procedures, it should meet the following requirements:

  • TAVI interventions may only be carried out in hospitals with a department of internal medicine and cardiology;
  • TAVI interventions can be carried out by jointly operated facilities of two legally independent hospitals if all the structural and process quality requirements of the guideline are met (e.g., the department of cardiology and cardiac surgery should be located close to each other);
  • To offer a clip procedure on the mitral valve, the hospital must have at least one of two cardiology and cardiac surgery departments in one building.

The evaluation report has to be submitted by December 31, 2019.

See full details in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

03

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Read more

07

Feb 2022

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

Read more

28

Jan 2022

On December 26, 2021, the new health app was introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 28 health apps are now available at the DiGA Directory.

Read more